Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
ASCO 2022
It's been a jam-packed morning here in Glasgow at #IMS26! 🏴
From new data to clinical practice insights, we've covered a lot of ground in #MultipleMyeloma with experts including @DrOlaLandgren, @YiLinMDPhD, @MyMKaiser, and Elena Zamagni.
🎥 Stay tuned on
It's our final day at #IMS26! 🏴 📣
Thank you to Luciano Costa (@End_myeloma) for stopping by just now to share insights from the MajesTEC-3 post hoc analysis, comparing tec-dara with dara-based triplets in R/R #MultipleMyeloma.
#Myeloma #MMsm #TrialUpdates #CTSM
Lovely to catch up with @Mohty_EBMT just now at #IMS26! 🏴
🎥 He shared key highlights from the meeting so far. Watch out for his insights, coming soon to https://VJHemOnc.com!
#MMsm #MultipleMyeloma #Myeloma @Myeloma_Society
We're rounding out day 2 of #IMS26 by speaking with @FrancescoMaura4!
He covered topics including genomics and epigenetics, t(11;14) in treatment-naïve GPRC5D-negative #MultipleMyeloma, and the sequencing of CELMoDs. 🧬 🎥
#MMsm @Myeloma_Society
It was great speaking with @DrRakeshPopat this afternoon at #IMS26 to discuss the interim results from the ProMMise D study and gain insights into the CEVOLUTION trial.
Full interview coming soon to https://VJHemOnc.com 📽️ 👀
#MMsm #MultipleMyeloma #Myeloma @Myeloma_Society
ASCO 2022
It's been a jam-packed morning here in Glasgow at #IMS26! 🏴
From new data to clinical practice insights, we've covered a lot of ground in #MultipleMyeloma with experts including @DrOlaLandgren, @YiLinMDPhD, @MyMKaiser, and Elena Zamagni.
🎥 Stay tuned on
It's our final day at #IMS26! 🏴 📣
Thank you to Luciano Costa (@End_myeloma) for stopping by just now to share insights from the MajesTEC-3 post hoc analysis, comparing tec-dara with dara-based triplets in R/R #MultipleMyeloma.
#Myeloma #MMsm #TrialUpdates #CTSM
Lovely to catch up with @Mohty_EBMT just now at #IMS26! 🏴
🎥 He shared key highlights from the meeting so far. Watch out for his insights, coming soon to https://VJHemOnc.com!
#MMsm #MultipleMyeloma #Myeloma @Myeloma_Society
We're rounding out day 2 of #IMS26 by speaking with @FrancescoMaura4!
He covered topics including genomics and epigenetics, t(11;14) in treatment-naïve GPRC5D-negative #MultipleMyeloma, and the sequencing of CELMoDs. 🧬 🎥
#MMsm @Myeloma_Society
It was great speaking with @DrRakeshPopat this afternoon at #IMS26 to discuss the interim results from the ProMMise D study and gain insights into the CEVOLUTION trial.
Full interview coming soon to https://VJHemOnc.com 📽️ 👀
#MMsm #MultipleMyeloma #Myeloma @Myeloma_Society
